Picton Mahoney Asset Management Has $2.91 Million Stock Holdings in PRA Health Sciences Inc (NASDAQ:PRAH)

Picton Mahoney Asset Management trimmed its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 5.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 29,300 shares of the medical research company’s stock after selling 1,600 shares during the quarter. Picton Mahoney Asset Management’s holdings in PRA Health Sciences were worth $2,905,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sloane Robinson LLP boosted its holdings in PRA Health Sciences by 4,100.0% during the second quarter. Sloane Robinson LLP now owns 117,600 shares of the medical research company’s stock worth $11,660,000 after purchasing an additional 114,800 shares during the last quarter. Signition LP boosted its holdings in PRA Health Sciences by 3.6% during the second quarter. Signition LP now owns 15,856 shares of the medical research company’s stock worth $1,572,000 after purchasing an additional 550 shares during the last quarter. Parallel Advisors LLC raised its position in PRA Health Sciences by 33.5% in the second quarter. Parallel Advisors LLC now owns 2,409 shares of the medical research company’s stock worth $239,000 after acquiring an additional 605 shares during the period. State Board of Administration of Florida Retirement System raised its position in PRA Health Sciences by 1.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 83,357 shares of the medical research company’s stock worth $8,265,000 after acquiring an additional 920 shares during the period. Finally, Swiss National Bank raised its position in PRA Health Sciences by 2.9% in the second quarter. Swiss National Bank now owns 109,758 shares of the medical research company’s stock worth $10,883,000 after acquiring an additional 3,100 shares during the period. Hedge funds and other institutional investors own 95.34% of the company’s stock.

Shares of NASDAQ PRAH traded down $2.35 during midday trading on Friday, hitting $95.37. The company’s stock had a trading volume of 332,241 shares, compared to its average volume of 652,635. The stock has a fifty day moving average price of $98.18 and a 200 day moving average price of $99.68. PRA Health Sciences Inc has a one year low of $82.12 and a one year high of $121.98. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 1.11. The firm has a market capitalization of $6.44 billion, a price-to-earnings ratio of 24.27, a P/E/G ratio of 1.32 and a beta of 1.12.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.11. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The company had revenue of $763.31 million for the quarter, compared to analyst estimates of $764.95 million. During the same quarter in the previous year, the firm posted $1.00 earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, equities research analysts predict that PRA Health Sciences Inc will post 4.63 earnings per share for the current fiscal year.

Several analysts have commented on the stock. Mizuho set a $100.00 price objective on shares of PRA Health Sciences and gave the stock a “hold” rating in a research report on Friday, May 3rd. BidaskClub raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Leerink Swann assumed coverage on shares of PRA Health Sciences in a research report on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 price objective on the stock. Finally, Svb Leerink reaffirmed a “market perform” rating on shares of PRA Health Sciences in a research report on Tuesday, July 2nd. Eight analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $113.40.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Further Reading: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.